ClinicalTrials.gg
Active, not recruitingNCT05994131Updated Nov 12, 2026

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

A Phase 1/2 interventional study of IN10018 and Furmonertinib in NSCLC, sponsored by InxMed (Shanghai) Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by InxMed (Shanghai) Co., Ltd. · Phase 1/2, Interventional, and Treatment

Updated Nov 12, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label, phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and antitumor efficacy of IN10018 in combination with third-generation EGFR-TKI (Furmonertinib is the proposed) in previously-treated or naïve advanced EGFR-mutation positive NSCLC.

Read the detailed description

This study includes 2 parts: Phase Ib-Dose Confirmation and Phase II-Dose Expansion. And 3 cohorts are set up in this study as cohort 1 to enroll subjects currently accepting third-generation EGFR-TKI (Furmonertinib is proposed) as first-line treatment, cohort 2 to enroll subjects who previously accepted third-generation EGFR-TKI treatment and 1-2 lines chemotherapy, and cohort 3 to enroll treatment-naive advanced EGFR mutation-positive NSCLC subjects.

The phase Ib-dose confirmation part will be conducted in cohort 2 and aim to determine the recommended phase II dose (RP2D) of IN10018 in combination with Furmonertinib. Phase II-Dose Expansion part will be conducted in cohort 1-3 and further explore the antitumor efficacy, safety and PK of IN10018 in combination with Furmonertinib in subjects with previously-treated or naïve advanced EGFR mutation-positive NSCLC.

02

Conditions studied

  • NSCLC

Keywords

  • EGFR mutation-positve
03

In context

Lead sponsor

InxMed (Shanghai) Co., Ltd. is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able to understand and be willing to sign .
  2. Male or female aged ≥ 18 years old at the time of signing informed consent.
  3. or cytologically confirmed locally advanced or NSCLC, who is not suitable for radical surgery or radiotherapy.
  4. Documented EGFR mutations known to be associated with EGFR-TKI sensitivity, including Ex19del or L858R. Except for EGFR-TKI sensitive mutation, coexisting with other EGFR mutation types such as T790M can be allowed.
  5. Prior systemic antitumor therapy allowed are listed as follows:

    • Cohort 1: Subjects who are on the treatment of Furmonertinib as the treatment setting.
    • Cohort 2: Subjects failed in third-generation EGFR-TKI treatment and also failed in or were intolerant to 1-2 lines of chemotherapy.
    • Cohort 3: subjects who haven't accepted any systemic therapy before. Prior or neoadjuvant chemotherapy is permitted if an interval from the lost dose of adjuvant or neoadjuvant chemotherapy to the first documented PD is >6 months.
  6. at baseline according to 1.1 criteria.
  7. Has an performance status of 0 or 1.
  8. Estimated is more than 3 months.
  9. Adequate bone marrow, liver, renal, and coagulation function within 7 days prior to the first dose of study treatment/randomization.

Exclusion criteria

Exclusion Criteria

  1. Have experienced major surgical procedures or major trauma within 28 days prior to the first dose of study treatment/randomization.
  2. Have received the following prior systemic antitumor therapy:

    • Cohort 1: Have received chemotherapy, target therapy besides Furmonertinib, immunotherapy, biological therapy, and other antitumor drugs.
    • Cohort 2: Have received chemotherapy, targeted therapy, immunotherapy, biological therapy, and other antitumor drugs within 28 days prior to the first dose of study treatment.
    • Cohort 3: Have received systemic antitumor therapy for locally-advanced or NSCLC including chemotherapy, target therapy, immunotherapy, biotherapy, etc.
  3. Cohort 2 only: Presence of other gene mutations, including ALK mutation, MET amplification, amplification, RAS mutation, etc. after progression on prior third-generation EGFR-TKI treatment.
  4. Cohort 3 only:Has received the treatment of EGFR-TKI。
  5. Prior FAK inhibitors treatment.
  6. Have received systemic administration of potent inhibitors/inducers of , or P-gp inhibitors within 14 days prior to the first dose of treatment/randomization or are expected to receive systemic administration of these drugs during study treatment.
  7. Has received radiotherapy for study disease or radiotherapeutic area covered for more than 30% of the bone marrow within 28 days prior to the first dose of study treatment/randomization.
  8. Has had interstitial lung disease (ILD), drug-induced ILD, radiation pneumonia requiring therapy; or diagnosis of clinically active ILD during the screening period.
  9. Has a prior history of other within 3 years prior to signing .
  10. Has known symptoms of spinal cord compression, active central nervous system (CNS) metastases, and/or carcinomatous meningitis.
  11. Has a history of severe cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study treatment/randomization.
  12. Has known uncontrollable pleural effusion, pericardial effusion, and ascites.
  13. Has hemoptysis within 1 month prior to the first dose of study treatment/randomization with a blood volume of ≥2.5 mL every time or expected to require continuous hemostasis therapy during the study treatment.
  14. Has active infections that are poorly controlled by systemic treatment.
  15. Has active tuberculosis.
  16. Known allergy, or intolerance to IN10018 and/or third-generation EGFR-TKI, or their ingredients.
  17. Pregnant or lactating women.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Experimental Group in cohort 1, cohort 2, and cohort 3

    IN10018+Furmonertinib

    Drug: IN10018 · Drug: Furmonertinib

  • Active comparator
    Control Group in cohort 3

    Furmonertinib

    Drug: Furmonertinib

Interventions

06

What researchers measure

Primary outcomes

  1. Recommended phase II dose (RP2D) of IN10018 in combination with third-generation EGFR-TKI in subjects with advanced EGFR mutation-positive NSCLC.

    Evaluate the number of patients with dose-limited toxicities (DLTs); Determine the RP2D of IN10018 in combination with third-generation EGFR-TKI in subjects with advanced NSCLC.

    Time frame: 3 years

  2. ORR of IN10018 in combination with third-generation EGFR-TKI in subjects with advanced EGFR mutation-positive NSCLC.

    Defined as the proportion of subjects with complete response (CR) or partial response (PR)

    Time frame: 3 years

  3. Tumor Shrinkage Rate (TSR) of IN10018 in combination with third-generation EGFR-TKI in cohort 3 of advanced treatment-naive EGFR mutation-positive NSCLC.

    Defined as the percentage of subjects with the best shrinkage rate of target lesions ≥ 70% and simultaneously with a best response of partial response (PR) or complete response (CR).

    Time frame: 3 years

Secondary outcomes

  1. PFS of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.

    Defined as the time from the first dose of study treatment/randomization to first documentation of disease progression or to death due to any cause, whichever comes first.

    Time frame: 3 years

  2. DOR of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.

    Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first.

    Time frame: 3 years

  3. DCR of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.

    Defined as the proportion of patients with CR, PR, or stable disease (SD).

    Time frame: 3 years

  4. OS of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.

    Defined as the time from the first dose of study treatment/randomization to the date of death due to any cause.

    Time frame: 3 years

  5. Number of patients with adverse event

    The number of participants who experienced AEs is presented.

    Time frame: 3 years

  6. PK: AUC of IN10018 following single dose administration and at steady state

    Area under the concentration-time curve (AUC)

    Time frame: 3 years

  7. PK: Cmax of IN10018 following single dose administration and at steady state

    Maximum concentration (Cmax)

    Time frame: 3 years

  8. PK:Ctrough of IN10018 following single dose administration and at steady state

    Trough concentration (Ctrough)

    Time frame: 3 years

  9. PK:Tmax of IN10018 following single dose administration and at steady state

    Time to Cmax (Tmax)

    Time frame: 3 years

  10. PK:t1/2 of IN10018 following single dose administration and at steady state

    Elimination half-life (t1/2).

    Time frame: 3 years

  11. PK:CL/F of IN10018 following single dose administration and at steady state

    apparent clearance (CL/F)

    Time frame: 3 years

  12. PK:Vd/F of IN10018 following single dose administration and at steady state

    Apparent volume of distribution (Vd/F)

    Time frame: 3 years

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2023 to primary completion in Sep 2025, 26 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jul 2026 → Sep 2025 and completion Jul 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2023
First posted
Aug 16, 2023
StartActual
Jul 13, 2023
Primary completionActual
Sep 20, 2025was Jul 2026
CompletionEst.
Dec 31, 2026was Jul 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 12, 2026
Primary completion
Jul 31, 2026→Sep 20, 2025 (actual)
Nov 12, 2026
Study completion
Jul 31, 2026→Dec 31, 2026
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Active, not recruiting
    Primary completion Jul 31, 2026→Sep 20, 2025 (now actual)
    Study completion Jul 31, 2026→Dec 31, 2026
    + 5 other changes: verification date, oversight details, contact details, site details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05994131
Lead sponsor
InxMed (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Aug 16, 2023
Start date
Jul 13, 2023
Primary completion
Sep 20, 2025
Completion
Dec 31, 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Caicun Zhou
principal investigator · Shanghai Pulmonary Hospital, Shanghai, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ifebemtinib

Start the discussion